A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
NCT ID: NCT03909971
Last Updated: 2025-11-05
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
109 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-04-28
Study Completion Date
2024-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
NCT06092086
ALK Positive Non-small Cell Lung Cancer
RECRUITING
PHASE2
Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC
NCT06904547
ALK-Positive NSCLC
NOT_YET_RECRUITING
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING
PHASE2
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
NCT04541706
Advanced Non-Small Cell Lung Cancer
COMPLETED
PHASE4
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
NCT06876675
Non-Small Cell Lung Cancer
Hyperlipidemia
ENROLLING_BY_INVITATION
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase 2, China only, multi center, open label, dual cohort study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive lorlatinib monotherapy.
* (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor.
* (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
* (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor.
* (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Carcinoma, Non-Small-Cell Lung
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lorlatinib
Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Group Type
EXPERIMENTAL
Lorlatinib
Intervention Type
DRUG
ALK inhibitor-treated ALK-positive NSCL treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorlatinib
ALK inhibitor-treated ALK-positive NSCL treatment
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PF-06463922
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).
2. Subject should have:
1. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;
2. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.
3. Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.
4. All Subjects must have at least 1 measurable extracranial target lesion according to RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:
1. Asymptomatic: either not currently requiring corticosteroid treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or
2. Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.
6. Age 18 years (or 20 years as required by local regulation).
7. Adequate bone marrow functions:
1. Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;
2. Platelets 100,000/mm3 or 100 x 109/L;
3. Hemoglobin 9 g/dL.
8. Adequate pancreatic function:
1. Serum total amylase 1.5 x upper limit of normal (ULN);\*
2. Serum lipase 1.5 x ULN. \*if total amylase \>1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.
9. Adequate renal function:
a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution.
10. Adequate liver function:
1. Total serum bilirubin 1.5 x ULN;
2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).
11. Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.
12. Serum or urine pregnancy test (for females of childbearing potential) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:
1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;
2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
3. Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
13. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
14. Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.
2. Subject should have:
1. (in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;
2. (in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.
3. Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.
4. All Subjects must have at least 1 measurable extracranial target lesion according to RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:
1. Asymptomatic: either not currently requiring corticosteroid treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or
2. Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.
5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.
6. Age 18 years (or 20 years as required by local regulation).
7. Adequate bone marrow functions:
1. Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;
2. Platelets 100,000/mm3 or 100 x 109/L;
3. Hemoglobin 9 g/dL.
8. Adequate pancreatic function:
1. Serum total amylase 1.5 x upper limit of normal (ULN);\*
2. Serum lipase 1.5 x ULN. \*if total amylase \>1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.
9. Adequate renal function:
a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution.
10. Adequate liver function:
1. Total serum bilirubin 1.5 x ULN;
2. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).
11. Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.
12. Serum or urine pregnancy test (for females of childbearing potential) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:
1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;
2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
3. Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.
13. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
14. Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.
Exclusion Criteria
Subjects with any of the following characteristics/conditions will not be included in the study:
1. More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic setting.
If disease recurred/relapsed within the adjuvant chemotherapy treatment or \<=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the first line systemic chemotherapy to the disease.
2. Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.
3. Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.
4. Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).
5. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.
6. Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.
7. Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.
8. Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.
9. Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.
10. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
11. Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:
* Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack -TIA), myocardial infarction, unstable angina;
* Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;
* Nonvascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval \>220 msec; or
* Ongoing cardiac dysrhythmias of CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read electrocardiogram (ECG) with QTc \>470 msec, or congenital long QT syndrome.
12. Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.
13. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
14. Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.
15. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:
1. Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits \[eg, Seville oranges, pomelos\], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;
2. Known CYP3A substrates with narrow therapeutic index, such as astemizole\*, terfenadine\*, cisapride\*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (\*withdrawn from US market);
3. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);
4. Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).
16. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.
17. Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
18. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
19. Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.
1. More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic setting.
If disease recurred/relapsed within the adjuvant chemotherapy treatment or \<=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the first line systemic chemotherapy to the disease.
2. Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.
3. Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.
4. Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).
5. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.
6. Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.
7. Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.
8. Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.
9. Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.
10. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
11. Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:
* Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack -TIA), myocardial infarction, unstable angina;
* Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;
* Nonvascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval \>220 msec; or
* Ongoing cardiac dysrhythmias of CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read electrocardiogram (ECG) with QTc \>470 msec, or congenital long QT syndrome.
12. Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.
13. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.
14. Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.
15. Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:
1. Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits \[eg, Seville oranges, pomelos\], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;
2. Known CYP3A substrates with narrow therapeutic index, such as astemizole\*, terfenadine\*, cisapride\*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (\*withdrawn from US market);
3. Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);
4. Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).
16. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.
17. Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
18. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
19. Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University
Hefei, Anhui, China
Site Status
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Site Status
Fujian Province Oncology Hospital
Fuzhou, Fujian, China
Site Status
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Site Status
Hunan Provincial Tumor Hospital/Division of Oncology
Changsha, Hunan, China
Site Status
The first hospital of jilin university
Changchun, Jilin, China
Site Status
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
Site Status
Tangdu Hospital of Fourth Military Medical University
Xi’an, Shanxi, China
Site Status
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
Chengdu, Sichuan, China
Site Status
West China Hospital, Sichuan University, Cancer center
Chengdu, Sichuan, China
Site Status
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, China
Site Status
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
Hangzhou, Zhejiang, China
Site Status
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Site Status
Fifth Medical Center of PLA General Hospital
Beijing, , China
Site Status
Beijing Chest Hospital, Capital Medical University
Beijing, , China
Site Status
Guangdong Provincial People's Hospital
Guangzhou, , China
Site Status
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, , China
Site Status
General Hospital of Eastern Theater Command
Nanjing, , China
Site Status
Shanghai Chest Hospital
Shanghai, , China
Site Status
Fudan University Shanghai Cancer Center
Shanghai, , China
Site Status
Zhongshan Hospital, Fudan University
Shanghai, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Niu R, Zhang Y, Pang J, Zhou Q, Lei Y, Du Y. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report. Front Oncol. 2024 Jan 26;14:1341233. doi: 10.3389/fonc.2024.1341233. eCollection 2024.
Reference Type
DERIVED
Lu S, Zhou Q, Liu X, Du Y, Fan Y, Cheng Y, He S, Zhao H, Li H, Wu YL. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer. Clin Lung Cancer. 2024 Nov;25(7):e295-e303.e4. doi: 10.1016/j.cllc.2024.04.017. Epub 2024 Apr 30.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
https://pmiform.com/clinical-trial-info-request?StudyID=B7461024
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCT03909971
Identifier Type: REGISTRY
Identifier Source: secondary_id
B7461024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
NCT04127110
ACTIVE_NOT_RECRUITING
PHASE2
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
NCT06858410
NOT_YET_RECRUITING
PHASE3
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
NCT04979988
COMPLETED
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608
ACTIVE_NOT_RECRUITING
PHASE3
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874
NOT_YET_RECRUITING
PHASE4
Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC
NCT06690541
NOT_YET_RECRUITING
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
NCT04111705
COMPLETED
PHASE2
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
NCT07083687
NOT_YET_RECRUITING
PHASE2
Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT03178071
NO_LONGER_AVAILABLE
Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
NCT03998085
UNKNOWN
NA
Lorlatinib Continuation Study
NCT05144997
ACTIVE_NOT_RECRUITING
PHASE4
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
NCT05740943
ACTIVE_NOT_RECRUITING
PHASE2
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
NCT06893354
NOT_YET_RECRUITING
PHASE4
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
NCT02927340
UNKNOWN
PHASE2
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
NCT03059797
COMPLETED
PHASE2
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
NCT06634667
NOT_YET_RECRUITING
PHASE2
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
NCT03703596
UNKNOWN
PHASE2
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03922997
COMPLETED
PHASE3
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
NCT03672643
TERMINATED
PHASE4
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
NCT06463171
NOT_YET_RECRUITING
PHASE2
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
NCT06487078
RECRUITING
NA
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
NCT06361589
RECRUITING
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
NCT04675697
UNKNOWN
PHASE2
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
NCT03123484
UNKNOWN
PHASE2
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
NCT01924195
COMPLETED
PHASE2